Cassava Sciences, Inc. (SAVA)
|52 Week Range||2.78-146.16|
|1y Target Est||-|
|Debt / Equity||1.02%||Neutral|
Upgrades & Downgrades
Detours In The Golden Age Of Alzheimer's Drug Stock Investments
Biogen's Aduhelm performed no better than placebo in non-ApoE4 carriers and only slightly slowed down the progression of Alzheimer's disease in ApoE4 carriers. ...
SAVA Stock Price Increases Over 17% Intraday: Why It Happened
The stock price of Cassava Sciences Inc (NASDAQ: SAVA) increased by over 17% during intraday trading. This is why it happened. ...
Cassava Sciences Stock Has Been Hammered For No Good Reason and Is Likely To Rebound
Cassava Sciences stock has been hammered for no good reason and is likely to rebound. AVA stock is still worth over $900 especially given the recent positive 9-month results of its Alzheimer's drug Simufilam. ...
Why Former NYSE Trader David Green Bought NVIDIA, Tesla, and Cassava Sciences On Tuesday
Veteran trader David Green was back live trading on Benzinga Tuesday morning, and the long-time trader made some moves. Green pointed out the strength of NVIDIA Corporation (NASDAQ:NVDA) Tuesday morning. ...
Cassava Sciences Reports Second Quarter 2021 Financial Results
- Conference Call Today at 9 a.m. ET - - Conference Call Today at 9 a.m. ET - ...
5 Ultra-Popular Stocks to Avoid Like the Plague in August
These stocks look to be more trouble than they're worth. ...
The Motley Fool
Cassava Sciences Announces Conference Call for Second Quarter Financial Results
- Call-in on Tuesday, August 3rd at 9 a.m. ET - - Call-in on Tuesday, August 3rd at 9 a.m. ET - ...
Cassava Sciences' Simufilam Is The First Alzheimer's Drug To Work At 9 Months, And The Benefit Is Gr...
Simufilam is the first AD drug to show a cognitive improvement at 9 months, with a gaudy 18% mean improvement from baseline. Simufilam also showed a growing behavioral benefit. ...
SAVA Stock Fell 23.61%: Details You Should Know
The stock price of Cassava Sciences Inc (NASDAQ: SAVA) fell by over 25% during intraday trading. These are some details you should know. ...
Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data
As Cassava Sciences made progress in treating Alzheimer's, SAVA stock is on a powerful path to significantly higher prices. The post Cassava Sciences Stock Has Plenty of Momentum After Positive Clinical Data appeared first on InvestorPlace. ...